Total raised
$121.0M
Last: Series D 2024-10
Stage
Series D
Founded
2015
Headcount
86
HQ
Herzliya
Sector
Health Tech & Life Sciences
About
Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, for presbyopia as an alternative to reading glasses. Presbyopia is the gradual loss of your eye’s ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide.
Orasis is led by a collaborative team of industry executives, Optometrists and Ophthalmologists with a diverse set of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development.
Funding history · 5 rounds · $121.0M total
2024-10
Series D
$78.0M
2022-05
Undisclosed
Undisclosed
2020-09
Series C
$30.0M
2018-06
Series B
$13.0M
2016-01
Series A
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsophthalmologydrug-discoveryeye-diseases